Inclusion Criteria:
- Patients with a primary diagnosis of melanoma with involvement of lymph nodes or
metastatic disease who have undergone complete resection and have no evidence of
disease.
- Decision to treat with adjuvant nivolumab therapy has already been taken
- At least 18 years of age at the time of treatment decision
- Patients who provide written informed consent to participate in the study (for
retrospectively enrolled patients who are deceased at time of study start, a consent
waiver will be sought)
Exclusion Criteria:
- Any patient with a diagnosis of persisting advanced melanoma prior to first
administration of nivolumab
- Any patient currently enrolled in an interventional clinical trial for his/her
melanoma treatment (note: patients who have completed their participation in an
interventional trial or who are no longer receiving the study drug and are only
followed up for Overall Survival (OS)/ Relapse Free Survival (RFS) can be enrolled. In
case of a blinded study, the treatment arm needs to be known).
Other protocol defined inclusion/exclusion criteria could apply
Active, Not Recruiting
